scholarly journals Current Concepts in Biomarker Technology for Bladder Cancers

2000 ◽  
Vol 46 (5) ◽  
pp. 595-605 ◽  
Author(s):  
Martin Burchardt ◽  
Tatjana Burchardt ◽  
Ahmad Shabsigh ◽  
Alexandre De La Taille ◽  
Mitchell C Benson ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Matrix Protein ◽  
Transitional Cell ◽  
High Sensitivity ◽  
Diagnostic Techniques ◽  
Single Marker ◽  
Cell Cycle Regulatory Proteins ◽  
Standard Of Practice ◽  
Carcinoma Of The Bladder ◽  
Potential Biomarkers

Abstract Background: Transitional cell carcinoma of the bladder (TCC) is the second most common malignancy of the urinary tract. More than 70% of treated tumors recur, and 30% of recurrent tumors progress. Currently, pathologic staging and grading are valuable prognostic factors for detecting and monitoring TCC. Urinalysis, cystoscopy, and cytology are either invasive or lack sensitivity and specificity. The availability of a noninvasive, reliable, and simple test would greatly improve the detection and monitoring of patients with TCC. Several biomarkers for bladder cancer have been proposed, but no single marker has emerged as the test of choice. Approach: We undertook a comprehensive literature search using Medline to identify all publications from 1980 to 1999. Articles that discussed potential biomarkers for TCC were screened. Only compounds that demonstrated high sensitivity or specificity, significant correlation with TCC diagnosis and staging, and extensive investigation were included in this review. Content: Potential biomarkers of disease progression and prognosis include nuclear matrix protein, fibrin/fibrinogen product, bladder tumor antigen, blood group-related antigens, tumor-associated antigens, proliferating antigens, oncogenes, growth factors, cell adhesion molecules, and cell cycle regulatory proteins. The properties of the biomarkers and the methods for detecting or quantifying them are presented. Their sensitivities and specificities for detecting and monitoring disease were 54–100% and 61–97%, respectively, compared with 20–40% and 90% for urinalysis and cytology. Summary: Although urine cytology and cystoscopy are still the standard of practice, many candidate biomarkers for TCC are emerging and being adopted into clinical practice. Further research and better understanding of the biology of bladder cancer, improved diagnostic techniques, and standardized interpretation are essential steps to develop reliable biomarkers. It is possible that using the current biomarkers as an adjuvant modality will improve our ability to diagnose and monitor bladder cancer.

Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer

Urology ◽  
2003 ◽  
Vol 61 (3) ◽  
pp. 539-543 ◽  
Author(s):  
Scott M Gilbert ◽  
Robert W Veltri ◽  
Alex Sawczuk ◽  
Ahmad Shabsigh ◽  
David R Knowles ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
History Of ◽  
Carcinoma Of The Bladder

scholarly journals Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Matteo Santoni ◽  
Francesco Catanzariti ◽  
Daniele Minardi ◽  
Luciano Burattini ◽  
Massimo Nabissi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Matrix Protein ◽  
Transitional Cell ◽  
High Recurrence Rate ◽  
Diagnostic Potential ◽  
Bladder Cancer Cells ◽  
Previously Treated Patients ◽  
Previously Treated

Transitional cell carcinoma (TCC) of the bladder is one of the most common malignancies of genitourinary tract. Patients with bladder cancer need a life-long surveillance, directly due to the relatively high recurrence rate of this tumor. The use of cystoscopy represents the gold standard for the followup of previously treated patients. Nevertheless, several factors, including cost and invasiveness, render cystoscopy not ideal for routine controls. Advances in the identification of specific alterations in the nuclear structure of bladder cancer cells have opened novel diagnostic landscapes. The members of nuclear matrix protein family BLCA-1 and BLCA-4, are currently under evaluation as bladder cancer urinary markers. They are involved in tumour cell proliferation, survival, and angiogenesis. In this paper, we illustrate the role of BLCA-1 and BLCA-4 in bladder carcinogenesis and their potential exploitation as biomarkers in this cancer.

Detection of Recurrent Transitional Cell Carcinoma of the Bladder with Nuclear Matrix Protein-22 in a Follow-up Setting

UroOncology ◽  
2003 ◽  
Vol 2 (3) ◽  
pp. 137-142
Author(s):  
J.W.A. Oosterhuis ◽  
R.P.E. Pauwels ◽  
R.F.M. Schapers ◽  
J. van Pelt ◽  
W. Smeets ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Nuclear Matrix ◽  
Matrix Protein ◽  
Transitional Cell ◽  
Nuclear Matrix Protein ◽  
Carcinoma Of The Bladder

Adjuvant Intravesical Chemotherapy in Patients with Primary T1 G3 Transitional Cell Carcinoma of the Bladder

1993 ◽  
Vol 60 (4) ◽  
pp. 345-348
Author(s):  
V. Serretta ◽  
S. Piazza ◽  
C. Pavone ◽  
G. Corselli ◽  
B. Piazza ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transitional Cell Carcinoma ◽  
Carcinoma In Situ ◽  
Transitional Cell ◽  
Invasive Disease ◽  
Intravesical Chemotherapy ◽  
Carcinoma Of The Bladder ◽  
Bladder Tumours

The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.

Adaptive genetic algorithms combined with high sensitivity single cell-based technology derived urine-based score to differentiate between high-grade and low-grade transitional cell carcinoma of the bladder.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 572-572
Author(s):  
Shaheen Riadh Alanee ◽  
Zade Roumayah ◽  
Musatafa Deebajah ◽  
James O. Peabody ◽  
Rodrigo Mora ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Bladder Cancer ◽  
Single Cell ◽  
Transitional Cell ◽  
Low Grade ◽  
High Grade ◽  
Median Score ◽  
Adaptive Genetic Algorithms ◽  
Cell Flow Cytometry ◽  
Carcinoma Of The Bladder

572 Background: We previously showed that adaptive genetic algorithms (AGA), in combination with single-cell flow cytometry technology, can be used to develop a noninvasive urine-based score to detect bladder cancer with high accuracy. Our aim in this analysis was to investigate if that same score can differentiate between high grade (HG) and low grade (LG) transitional cell carcinoma of the bladder (BC). Methods: We collected urine samples from cystoscopy confirmed HG and LG superficial bladder cancer patients and healthy donors in an optimized urine collection media. We then examined these samples using an assay developed from AGA in combination with single-cell flow cytometry technology. Results: We examined 50 BC and 15 healthy donor urine samples. Patients were majorly White (59.2%), males (61.2%), and had HG BC (66.7%). AGA derived score of 1.1 differentiated between BCa and healthy patients with high precision (AUC 0.92). The median score was 2.8 for LG BC and 6 for LG BC. Mann-Whitney Rank Sum Test indicated that the difference between the median score of HG and LG BC was significant at P value = 0.003. The score performed well independent of patients’ sex or smoking history. Conclusions: Using single-cell technology and machine learning, we developed a new urine-based score that can potentially differentiate between HG and LG bladder cancer. Future studies are planned to validate this score.

First-Line Chemotherapy with Cisplatin, Methotrexate and Vinblastine in Metastatic Bladder Cancer

1996 ◽  
Vol 82 (5) ◽  
pp. 453-455 ◽  
Author(s):  
Bojana Pajk ◽  
Tanja Čufer ◽  
Jozica Červek ◽  
Branko Zakotnik
Keyword(s):  
Bladder Cancer ◽  
Side Effects ◽  
Complete Remission ◽  
Soft Tissues ◽  
Transitional Cell ◽  
First Line ◽  
Carcinoma Of The Bladder ◽  
Metastatic Sites ◽  
Line Chemotherapy ◽  
Grade Iii

To determine the effectiveness of combination chemotherapy with cisplatin, methotrexate and vinblastine (CMV), we treated 21 chemotherapy naive patients with metastatic transitional cell carcinoma of the bladder. Chemotherapy consisted of methotrexate (30 mD/m2 i.v. days 1 and 8), vinblastine (3 mg/m2i.v. days 1 and 8) and cisplatin (100 mg/m2 i.v. day 2) every three weeks. Dominant metastatic sites were: soft tissues (7 patients), bone (6 patients), lung and liver (8 patients). A complete remission was achieved in 5/21 patients (24%, 95% CI 8-47%) and partial remission in 9/21 patients (43%, 95% CI 22-66%). The median duration was 6 months (2-11) and 9 months (2-26) for complete and partial remissions, respectively. The median survival for all 21 patients was 10 months. Although overall toxicity was mild, we observed myelosuppression grade IV in 2 patients, stomatitis grade III in 2 patients, cystitis grade III in 1 patient and infection grade III in 6 patients. There were no treatment-related deaths. Our data indicate that treatment with the CMV regimen is effective and that side effects are tolerable.

Sign in / Sign up

Export Citation Format

Share Document